SPRUCE BIOSCIENCES, INC.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
SPRB$46.67-5.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Additional · Total | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Accumulated · Stockholders’ | |||||||
| Shares · Amount · Capital · Deficit · Equity | |||||||
| Balance as of June 30, 2025 | 563,042 | $— | $279,556 | $(266,376) | $13,180 | ||
| Issuance of common stock related to employee stock purchase plan | 449 | 3 | 3 | ||||
| Stock-based compensation | — | — | 415 | — | 415 | ||
| Net loss | — | — | — | (8,212) | (8,212) | ||
| Balance as of September 30, 2025 | 563,491 | $— | $279,974 | $(274,588) | $5,386 | ||
| Additional · Total | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Accumulated · Stockholders’ | |||||||
| Shares · Amount · Capital · Deficit · Equity | |||||||
| Balance as of January 1, 2025 | 563,042 | $— | $279,089 | $(250,268) | $28,821 | ||
| Issuance of common stock related to employee stock purchase plan | 449 | 3 | 3 | ||||
| Stock-based compensation | — | — | 882 | — | 882 | ||
| Net loss | — | — | — | (24,320) | (24,320) | ||
| Balance as of September 30, 2025 | 563,491 | $— | $279,974 | $(274,588) | $5,386 | ||
| Additional · Total | |||||
|---|---|---|---|---|---|
| Common Stock · Paid-In · Accumulated · Stockholders’ | |||||
| Shares | Amount | Capital | Deficit | Equity | |
| Balance as of June 30, 2024 | 550,645 | $— | $277,207 | $(218,038) | $59,169 |
| Stock-based compensation | — | — | 1,140 | — | 1,140 |
| Net loss | — | — | — | (8,671) | (8,671) |
| Balance as of September 30, 2024 | 550,645 | $— | $278,347 | $(226,709) | $51,638 |
| Additional · Total | |||||
|---|---|---|---|---|---|
| Common Stock · Paid-In · Accumulated · Stockholders’ | |||||
| Shares | Amount | Capital | Deficit | Equity | |
| Balance as of January 1, 2024 | 547,019 | $— | $273,741 | $(197,232) | $76,509 |
| Exercise of common stock options | 1,595 | — | 180 | — | 180 |
| Issuance of common stock related to employee stock purchase plan | 1,576 | — | 52 | — | 52 |
| Issuance of common stock related to vesting of restricted stock units, net of tax withholdings | 455 | — | (13) | — | (13) |
| Stock-based compensation | — | — | 4,387 | — | 4,387 |
| Net loss | — | — | — | (29,477) | (29,477) |
| Balance as of September 30, 2024 | 550,645 | $— | $278,347 | $(226,709) | $51,638 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.